C 21 is a selective inhibitor of protein arginine methyltransferase 1 (PRMT1) (IC50 = 1.8 μM), which displays five-fold selectivity for PRMT1 over PRMT6 and >250-fold selectivity over PRMT3 and CARM1.
C 21, also known as Compound 21, is a selective non-peptide agonist of the angiotensin II type 2 receptor (AT2R), a critical component of the renin-angiotensin system (RAS). As a small-molecule modulator, C 21 has garnered significant attention in the biochemistry and pharmacology research communities for its ability to activate AT2R without affecting the angiotensin II type 1 receptor (AT1R). Its high selectivity and potency make it a valuable tool for elucidating the physiological and molecular roles of AT2R in various biological systems. By enabling precise manipulation of this receptor pathway, Compound 21 facilitates advanced studies into cardiovascular, renal, and neurological processes, expanding understanding of RAS beyond traditional paradigms.
Receptor pharmacology research: C 21 is widely utilized in receptor pharmacology to dissect the functional roles of AT2R in cell signaling and tissue physiology. Through selective activation of AT2R, researchers can differentiate the downstream effects mediated by this receptor from those driven by AT1R, which often have opposing biological outcomes. Such studies are fundamental for mapping the receptor-specific pathways involved in vasodilation, cellular proliferation, and tissue remodeling, providing a foundation for more nuanced models of RAS signaling.
Signal transduction studies: The compound serves as a powerful probe for investigating intracellular signaling cascades initiated by AT2R engagement. By employing C 21 in in vitro and in vivo systems, scientists can monitor changes in second messenger pathways, gene expression profiles, and protein phosphorylation events specific to AT2R activation. These insights are crucial for unraveling the unique molecular mechanisms underlying AT2R's regulatory functions in diverse tissues, including vascular, neural, and renal environments.
Disease model development: In preclinical research, Compound 21 is frequently applied to experimental models to explore the role of AT2R in the pathogenesis and progression of various diseases. Its selective agonist activity allows for targeted modulation of the RAS, enabling the assessment of AT2R's contribution to inflammation, fibrosis, and tissue repair processes. Such applications are instrumental in clarifying the receptor's protective or modulatory effects in conditions where RAS imbalance is implicated.
Drug screening and discovery: The use of C 21 extends to early-stage drug discovery, where it acts as a reference compound for screening novel AT2R ligands or antagonists. Its well-characterized pharmacological profile provides a benchmark for evaluating the potency, efficacy, and selectivity of new chemical entities targeting this receptor. This application supports the identification and optimization of candidate molecules for further research and development in the context of RAS modulation.
Physiological function elucidation: Compound 21 is instrumental in advancing knowledge of AT2R-mediated physiological processes at the organ and systemic levels. By enabling selective stimulation of AT2R, researchers can probe its involvement in blood pressure regulation, electrolyte homeostasis, neural signaling, and anti-inflammatory pathways. These studies help to delineate the broader biological significance of AT2R, informing both basic science and translational research efforts focused on the renin-angiotensin system.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More